Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia - The role of Bcl-2 family dysregulation

Leukemia Research

Volumn 23, Issue 11, 1999, Pages 1007-1014

  Pepper, Chris ^a   Thomas, Alun ^a   Hidalgo De Quintana, Juan ^a   Davies, Sharon ^a   Hoy, Terry ^b   Bentley, Paul ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; B CLL; Bax; Bcl 2; Drug resistance

Indexed keywords

ANTIINFECTIVE AGENT; CHLORAMBUCIL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE CONTROL; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPONSE TIME; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CHLORAMBUCIL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; PROTO-ONCOGENE PROTEINS C-BCL-2; VIDARABINE;

EID: 0032877142     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00122-8     Document Type: Article

References (20)

1. Robertson L.E., Plunkett W. Apoptotic cell death in chronic lymphocytic leukemia. Leuk. Lymphoma. 11:1993;71-74.
2. McConkey D.J., Chandra J., Wright S., Plunkett W., McDonnell T.J., Reed J.C., Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of Bcl-2 and Bax. J. Immunol. 156:1996;2624-2630.
3. Robertson L.E., Plunkett W., McConnell K., Keating M.J., McDonnell T.J. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 10:1996;456-459.
4. Schena M., Larsson L.-G., Gottardi D., Gaidano G., Carlsson M., Nilsson K., Caligaris-Cappio F. Growth and differentiation-associated expression of bcl-2 in chronic lymphocytic leukemia cells. Blood. 80:1992;2981-2989.
5. Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J.C. Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood. 82:1993;1820-1828.
6. Pepper C., Bentley P., Hoy T. Regulation of clinical chemoresistance by Bcl-2 and Bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 95:1996;513-517.
7. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., Wang H.-G., Zhang X., Bullrich F., Croce C.M., Rai K., Hines J., Reed J.C. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 91:1998;3379-3389.
8. Johnston J.B., Daeninck P., Verburg L., Lee K., Williams G., Israels L.G., Mowat M.R.A., Begleiter A. P53, mdm2, Bax and Bcl-2 and drug resistance in chronic lymphocytic leukemia. Leuk. Lymphoma. 26:1997;435-440.
9. Aguilar-Santelises M., Rottenberg M.E., Lewin N., Mellstedt H., Jondal M. Bcl-2, bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int. J. Cancer. 69:1996;114-119.
10. Pepper C., Hoy T., Bentley P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br. J. Cancer. 76:1997;935-938.
11. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 48:1981;198-206.
12. Ferlini C., Di Cesare S., Rainaldi G., Malorni W., Samoggia P., Biselli R., Fattorossi A. Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry. 24:1996;106-115.
13. Pepper C., Thomas A., Hoy T., Bentley P. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing sub-clones. Br. J. Haematol. 104:1999;581-588.
14. Silber R., Degar B., Costin D., Newcomb E.W., Mani M., Rosenberg C.R., Morse L., Drygas J.C., Canellakis Z.N., Potmesil M. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to Chlorambucil, Fludarabine and Camptothecin analogs. Blood. 84:1994;3440-3446.
15. Thomas A., El Rouby S., Reed J.C., Krajewski S., Silber R., Potmesil M., Newcomb E.W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 12:1996;1055-1062.
16. Jaksic B., Brugiatelli M., Suciu S., Baumelou E., Wijermans P.W., Delmer A., Roozendaal K.J., Teixeira A., Jehn U., Feremans W., Belhabri A., Venditti A., Indrak K., Rodts P., Solbu G., Willemze R. Randomized phase II study in untreated B-cell chronic lymphocytic leukemia (B-CLL) comparing Fludarabine (FAMP) versus high dose continuous Chlorambucil (HD-CLB). Blood. 92(1 (suppl)):1998;103a.
17. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
18. Jürgensmeier J.M., Xie Z., Deveraux Q., Ellerby L., Bredesen D., Reed J.C. Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl. Acad. Sci. 95:1998;4997-5002.
19. Beham A., Marin M.C., Fernandez A., Herrmann J., Brisbay S., Tari A.M., Lopez-Berestein G., Lozano G., Sarkiss M., McDonnell T.J. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 15:1997;2767-2772.
20. Voehringer D.W., McConkey D.J., McDonnell T.J., Brisbay S., Meyn R.E. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proc. Natl. Acad. Sci. 95:1998;2956-2960.